Bryan Remaily

Bryan Remaily's research focuses on how the body processes and clears cancer therapies, particularly monoclonal antibodies (lab-made proteins used in immunotherapy), and how factors like body composition and muscle wasting (cachexia) affect drug behavior and treatment outcomes in cancer patients. This work sits at the intersection of pharmacology, oncology, and physiology, aiming to improve dosing and predict responses to cancer immunotherapies. Prospective students would likely engage with clinical trial data, pharmacokinetic modeling, and biomarker analysis in cancer treatment contexts.

Publication output has grown from no papers before 2020 to a steady pace of about 2-4 papers per year since then, with continued activity projected into 2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026